People · Operator
Named in public records as an officer, director or promoter · active 2010–2019 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Dare Bioscience, Inc. | — | Biotechnology | Series B | $102.0M | $93.7M | 2010 |
| Lysosomal Therapeutics, Inc. | — | Biotechnology | Series B | $38.0M | $39.7M | 2019 |
| Esanex, Inc. | — | Pharmaceuticals | Series B | $18.1M | $87.9M | 2012 |
| Hydra Biosciences Inc | — | Biotechnology | Series A | $10.5M | $379.9M | 2015 |
Steven E. Hall at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Steven E. Hall on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Carpenter | 2 | 5 |
| Robert Langer | 1 | 36 |
| Bruce Booth | 1 | 12 |
| John P Ryan | 1 | 11 |
| Clay Thorp | 1 | 10 |
| Alan Crane | 1 | 9 |
| Terry McGuire | 1 | 8 |
| S Edward Torres | 1 | 8 |
| Robert Tepper | 1 | 7 |
| Daniel Geffken | 1 | 6 |
| Bryan E. Roberts | 1 | 6 |
| Jean George | 1 | 6 |
| Cheryl R. Blanchard | 1 | 4 |
| BERNARD DAVITIAN | 1 | 4 |
| Alexandra Glucksmann | 1 | 4 |
| Robert E. Langer | 1 | 3 |
| Paul Goldenheim | 1 | 3 |
| Peter Wirth | 1 | 3 |
| Henri Termeer | 1 | 3 |
| Carole Neuchterlein | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.